These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 3201650

  • 1. Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.
    Hansenson M, Lundh B, Hartley-Asp B, Pousette A.
    Urol Res; 1988; 16(5):357-61. PubMed ID: 3201650
    [Abstract] [Full Text] [Related]

  • 2. Difference in uptake of 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r.
    Hasenson M.
    Urol Res; 1989; 17(2):103-6. PubMed ID: 2734976
    [Abstract] [Full Text] [Related]

  • 3. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).
    Hartley-Asp B, Gunnarsson PO.
    J Urol; 1982 Apr; 127(4):818-22. PubMed ID: 7069864
    [Abstract] [Full Text] [Related]

  • 4. Effects of estramustine and its constituents on human malignant glioma cells.
    von Schoultz E, Lundgren E, Henriksson R.
    Anticancer Res; 1990 Apr; 10(3):693-6. PubMed ID: 2369085
    [Abstract] [Full Text] [Related]

  • 5. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research.
    Pousette A, Carlström K, Henriksson P, Grande M, Stege R.
    Prostate; 1997 May 15; 31(3):198-203. PubMed ID: 9167773
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
    Serafin AM, Akudugu JM, Bohm L.
    Urol Res; 2002 Oct 15; 30(5):289-94. PubMed ID: 12389116
    [Abstract] [Full Text] [Related]

  • 9. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME, Tew KD.
    Cancer Res; 1985 Aug 15; 45(8):3891-7. PubMed ID: 4016756
    [Abstract] [Full Text] [Related]

  • 10. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line.
    Kirschenbaum A, Ren M, Levine AC.
    Steroids; 1993 Sep 15; 58(9):439-44. PubMed ID: 8236330
    [Abstract] [Full Text] [Related]

  • 11. Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines.
    von Schoultz E, Lundblad D, Bergh J, Grankvist K, Henriksson R.
    Br J Cancer; 1988 Sep 15; 58(3):326-9. PubMed ID: 3052561
    [Abstract] [Full Text] [Related]

  • 12. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA.
    J Urol; 1980 Aug 15; 124(2):232-6. PubMed ID: 7190620
    [Abstract] [Full Text] [Related]

  • 13. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
    Mareel MM, Storme GA, Dragonetti CH, De Bruyne GK, Hartley-Asp B, Segers JL, Rabaey ML.
    Cancer Res; 1988 Apr 01; 48(7):1842-9. PubMed ID: 3349462
    [Abstract] [Full Text] [Related]

  • 14. Nuclear protein matrix as a target for estramustine-induced cell death.
    Hartley-Asp B, Kruse E.
    Prostate; 1986 Apr 01; 9(4):387-95. PubMed ID: 3786258
    [Abstract] [Full Text] [Related]

  • 15. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine.
    Essand M, Nilsson S, Carlsson J.
    Anticancer Res; 1993 Apr 01; 13(5A):1261-8. PubMed ID: 8239495
    [Abstract] [Full Text] [Related]

  • 16. Inhibition by estramustine phosphate on estradiol and androgen binding in benign and malignant prostate in humans.
    Nilsson I, Liskowski L, Nilsson T.
    Urology; 1976 Aug 01; 8(2):118-21. PubMed ID: 60819
    [Abstract] [Full Text] [Related]

  • 17. The effect of estramustine on microtubuli is different from the direct action via oxygen radicals on DNA and cell membrane.
    Henriksson R, Bjermer L, Von Schoultz E, Grankvist K.
    Anticancer Res; 1990 Aug 01; 10(2A):303-9. PubMed ID: 2346305
    [Abstract] [Full Text] [Related]

  • 18. Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCAP: role of interleukin-6.
    Okamoto M, Lee C, Oyasu R.
    Endocrinology; 1997 Nov 01; 138(11):5071-4. PubMed ID: 9348243
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells.
    de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F.
    Cancer Res; 1991 Jun 01; 51(11):2797-802. PubMed ID: 2032219
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.
    de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F.
    Cancer Res; 1991 Oct 01; 51(19):5165-70. PubMed ID: 1913642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.